2016

12/24/2016: Season's Greeting (2016)

12/08/2016: Chad Grochowski, the videographer of Journal of Visualized Experiments, filmed the video article on generating hepatic steatotic models in the Li lab. 

11/29/2016: Sun Yixuan was pre-admitted by Zhongshan Hospital, Fudan University for the standardized training on clinical internal medicine. 

11/18/2016: The Li lab attended the Chinese Diabetes Association (CDS)’s 20th scientific meeting in Xiamen. Congrats to Feifei Zhang for receiving the Excellent Poster Award at the CDS meeting in Xiamen. 

10/29/2016: Dr. Yu Li was invited to give a talk entitled “FGF21 in Control of Hepatic Insulin Sensitivity and Liver Disease” at Yuying International Conference on Translational Medicine, Wenzhou Medical University, Zhejiang

9/19/2016: Dr. Yu Li gave a talk at the Symposium on Pathophysiological Study of Endocrinology and Metabolic Diseases, the Second Military Medical University, Shanghai

 

7/02/2016: Dr. Yu Li gave a talk at 第四届西部两江糖尿病论坛 organized by the First Affiliated Hospital of Chongqing Medical University, FGF21 and Metabolic Diseases, Chongqing. 

 

6/11/2016: Li Lab’s Moderated Poster Discussion at the American Diabetes Association (ADA)’s 76th scientific meeting, and oral presentation at the Chinese American Diabetes Association (CADA) symposium in New Orleans, LA, USA.

 

5/25/2016: Dr. Yu Li gave a talk at the symposium of Lilly China Research and Development Center (LCRDC)-CAS Key Laboratory of Nutrition and Metabolism, Novel Nutrient Sensing Pathways in Regulating Type 2 Diabetes, Hepatic Steatosis and NASH, Shanghai. 

 

5/21/2016: Zhimin Hu received the third Prize of 6th Graduate Student Symposium of Institute for Nutritional Sciences, SIBS, CAS; and Aoyuan Cui received Graduate Scholarship sponsored by New World Development Company Limited, Hong Kong. 

 

5/14/2016: Li Lab organized a satellite tour for “Public Science Day” held by Chinese Academy of Sciences (CAS) and Chinese Society for Cell Biology (CSCB). 

 

4/29/2016: Congratulation to Aoyuan Cui for passing the PhD Qualifying Exam.

 

4/24/2016: Dr. Yu Li gave a talk at Shanghai International Conference on Digestive Diseases, FGF21 in Control of Hepatic Insulin Sensitivity and Liver Disease, Xinhua Hospital, Shanghai.

 

4/20/2016: Dr. Yu Li gave a talk at New Advances in Metabolism Research Symposium, FGF21 in the liver: hepatic steatosis, insulin sensitivity and type 2 diabetes, Duke-NUS Medical School, Singapore.

 

4/12/2016: Congratulation to Xuqing Chen for that her paper entitled “Hepatic ATF6 Increases Fatty Acid Oxidation to Attenuate Hepatic Steatosis in Mice through Peroxisome Proliferator-Activated Receptor Alpha” published at Diabetes. The manuscript was submitted on 30 November 2015, resubmitted on 17 March 2016, and finally accepted for publication on 6 April 2016. In the study, Xuqing Chen and her colleagues demonstrate a direct action of the key UPR sensor ATF6 on PPARα to improve hepatic fatty acid oxidation and control hepatic lipid homeostasis. This study supports the notion that ER stress-caused activation of the adaptation and/or recovery UPR pathways such as ATF6 restores lipid dysregulation and maintains metabolic homeostasis.

 

4/04/2016: Dr. Marschall HU, a leading expert in NAFLD, NASH and liver diseases, at University of Gothenburg of Sweden wrote an Editorial article highlighting the contribution of Qi Gong’s paper entitled “Fibroblast Growth Factor 21 Improves Hepatic Insulin Sensitivity by Inhibiting Mammalian Target of Rapamycin Complex 1” at Hepatology (PMID: 27042948). 

 

3/18/2016: Dr. Yu Li gave a talk at 第七届肥胖与糖尿病论坛, Shangyu, Zhejiang, China.

 

3/10/2016: Congratulation to Qi Gong for that her paper entitled “Fibroblast Growth Factor 21 Improves Hepatic Insulin Sensitivity by Inhibiting Mammalian Target of Rapamycin Complex 1” published at Hepatology. The manuscript was submitted on 4 October 2015, resubmitted on 25 January 2016, and finally accepted for publication on 24 February 2016. In the study, based on the recent findings that SIRT1 and RARβ act as potent upstream regulators of FGF21 (Li Y, et al, Gastroenterology, 2014; Li Y, et al, JBC, 2013), Qi Gong and her colleagues demonstrate that the hepatocyte-derived hormone FGF21 acts as a novel inhibitor of the nutrient sensor mTORC1 complex, and functions as an autocrine/paracrine in the modulation of hepatic insulin sensitivity and glucose homeostasis. 

Qi Gong, Zhimin Hu, Fengguang Ma and Chao Sun

STM with Dr. Yu Li in the lab

 

1/25/2016: Zhengshuai Liu and Fengguang Ma joined the lab as PhD students.